https://www.selleckchem.com/products/vy-3-135.html
Please see http//www.annualreviews.org/page/journal/pubdates for revised estimates. Loss of response (LOR) to infliximab (IFX) remains a challenge in the management of inflammatory bowel diseases (IBD). Proactive dosing strategies to achieve and maintain predefined IFX trough levels (TL) may prevent LOR. We aimed to investigate the efficacy of dashboard driven IFX dosing compared to standard dosing in a prospective trial in IBD patients. In this multicentre 11 'PRECISION' trial, we randomized IBD patients in clinical remission (Harvey
Aimer
Commentaire
Partagez
